Raffles Medical Group Ltd (SGX:BSL)
Singapore
· Delayed Price · Currency is SGD 1.030
+0.010 (0.98%)
Mar 6, 2026, 5:04 PM SGT
Raffles Medical Group Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 765.3 | 751.56 | 706.92 | 822.92 | 723.79 | Upgrade
|
| Other Revenue | - | 0.85 | 1.12 | 2.03 | 1.44 | Upgrade
|
| Revenue | 765.3 | 752.41 | 708.04 | 824.95 | 725.23 | Upgrade
|
| Revenue Growth (YoY) | 1.71% | 6.27% | -14.17% | 13.75% | 27.64% | Upgrade
|
| Cost of Revenue | 418.26 | 413.39 | 392.1 | 424.85 | 530.24 | Upgrade
|
| Gross Profit | 347.04 | 339.02 | 315.94 | 400.1 | 194.99 | Upgrade
|
| Selling, General & Admin | 168.56 | 168.47 | 138.31 | 109.2 | 5.44 | Upgrade
|
| Amortization of Goodwill & Intangibles | 1.57 | 1.55 | 1.53 | 1.93 | 2.6 | Upgrade
|
| Other Operating Expenses | 41.22 | 42.33 | 32 | 41.22 | 34.22 | Upgrade
|
| Operating Expenses | 256.37 | 253.94 | 207.76 | 186.83 | 76.79 | Upgrade
|
| Operating Income | 90.67 | 85.08 | 108.19 | 213.26 | 118.2 | Upgrade
|
| Interest Expense | -4.09 | -5.78 | -6.08 | -6.85 | -6.36 | Upgrade
|
| Interest & Investment Income | 7.33 | 10.25 | 9.76 | 2.74 | 0.63 | Upgrade
|
| EBT Excluding Unusual Items | 93.91 | 89.55 | 111.87 | 209.15 | 112.48 | Upgrade
|
| Impairment of Goodwill | -0.32 | -2.6 | - | -5.87 | -3.78 | Upgrade
|
| Asset Writedown | - | -0 | 7.4 | -12.03 | 0.41 | Upgrade
|
| Other Unusual Items | - | 0.02 | 0.17 | 0.08 | 6.47 | Upgrade
|
| Pretax Income | 93.59 | 86.96 | 119.44 | 191.34 | 115.58 | Upgrade
|
| Income Tax Expense | 22.52 | 24.68 | 28.35 | 47.94 | 31.87 | Upgrade
|
| Earnings From Continuing Operations | 71.07 | 62.28 | 91.09 | 143.4 | 83.72 | Upgrade
|
| Minority Interest in Earnings | -0.5 | -0.04 | -0.94 | -0.19 | 0.46 | Upgrade
|
| Net Income | 70.57 | 62.24 | 90.15 | 143.21 | 84.17 | Upgrade
|
| Net Income to Common | 70.57 | 62.24 | 90.15 | 143.21 | 84.17 | Upgrade
|
| Net Income Growth | 13.38% | -30.96% | -37.05% | 70.15% | 27.74% | Upgrade
|
| Shares Outstanding (Basic) | 1,850 | 1,857 | 1,859 | 1,857 | 1,868 | Upgrade
|
| Shares Outstanding (Diluted) | 1,854 | 1,861 | 1,869 | 1,866 | 1,876 | Upgrade
|
| Shares Change (YoY) | -0.36% | -0.41% | 0.12% | -0.54% | 1.96% | Upgrade
|
| EPS (Basic) | 0.04 | 0.03 | 0.05 | 0.08 | 0.05 | Upgrade
|
| EPS (Diluted) | 0.04 | 0.03 | 0.05 | 0.08 | 0.04 | Upgrade
|
| EPS Growth | 14.07% | -30.70% | -37.16% | 70.82% | 25.42% | Upgrade
|
| Free Cash Flow | 93.46 | 66.98 | 168.79 | 171.21 | 110.17 | Upgrade
|
| Free Cash Flow Per Share | 0.05 | 0.04 | 0.09 | 0.09 | 0.06 | Upgrade
|
| Dividend Per Share | 0.030 | 0.025 | 0.024 | 0.038 | 0.018 | Upgrade
|
| Dividend Growth | 20.00% | 4.17% | -36.84% | 111.11% | -28.00% | Upgrade
|
| Gross Margin | 45.35% | 45.06% | 44.62% | 48.50% | 26.89% | Upgrade
|
| Operating Margin | 11.85% | 11.31% | 15.28% | 25.85% | 16.30% | Upgrade
|
| Profit Margin | 9.22% | 8.27% | 12.73% | 17.36% | 11.61% | Upgrade
|
| Free Cash Flow Margin | 12.21% | 8.90% | 23.84% | 20.75% | 15.19% | Upgrade
|
| EBITDA | 132.88 | 115.09 | 132.9 | 239.72 | 143.3 | Upgrade
|
| EBITDA Margin | 17.36% | 15.30% | 18.77% | 29.06% | 19.76% | Upgrade
|
| D&A For EBITDA | 42.21 | 30.01 | 24.71 | 26.46 | 25.1 | Upgrade
|
| EBIT | 90.67 | 85.08 | 108.19 | 213.26 | 118.2 | Upgrade
|
| EBIT Margin | 11.85% | 11.31% | 15.28% | 25.85% | 16.30% | Upgrade
|
| Effective Tax Rate | 24.07% | 28.38% | 23.73% | 25.05% | 27.57% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.